If you spent any time shopping for sunscreen in South Korea or Japan, you may have come home genuinely confused. The formulas felt lighter. They didn’t leave that chalky residue. They went on like a serum and disappeared into the skin. The ingredient responsible for a lot of that difference is called bemotrizinol, and until June 9, 2026, you could not legally buy it in an American sunscreen. That changed this week.
The FDA added bemotrizinol to its list of permitted sunscreen active ingredients, marking the first new addition to the over-the-counter sunscreen monograph since the late 1990s. For anyone who has spent years reading ingredient labels and wondering why your sunscreen still relies on the same chemistry it did when Bill Clinton was in office, this is genuinely significant news.
The approval isn’t just a regulatory technicality. It reflects a longer story about why Americans have been buying inferior sun protection for decades, why that matters for skin cancer risk, and what the new sunscreen ingredient FDA approval actually does differently. The gap between the U.S. sunscreen market and what’s been available in Europe and Asia for twenty-plus years is not trivial, and understanding that gap helps explain why this particular approval lands the way it does.
What Bemotrizinol Actually Does
The active ingredients in a sunscreen are called UV filters. Their job is to intercept ultraviolet radiation before it damages the DNA in your skin cells. There are two types of UV radiation worth knowing about: UVB, the short-wavelength rays that cause sunburn, and UVA, the longer-wavelength rays that penetrate deeper, break down collagen, and play a significant role in skin aging and cancer, including melanoma.
UVB is high-energy radiation typically associated with sunburns and genetic mutations that lead to skin cancer, while UVA rays carry a longer wavelength that can penetrate deeper into the skin, breaking down its structure and creating harmful molecules linked to aging. Most existing chemical filters in U.S. sunscreens are strong against one or the other, not both at once. Companies compensate by mixing multiple filters to achieve what the label calls “broad spectrum” protection. That works, but it also means more ingredients, higher concentrations, and often a heavier, greasier feel on the skin.
Bemotrizinol covers both UVA and UVB rays and offers particularly strong coverage in the deeper UVA spectrum compared with other organic filters, according to a 2026 Scientific American report citing Saranya Wyles, a dermatologist at the Mayo Clinic. Those deeper UVA rays are often linked to photoaging of the skin.
Beyond its broad absorption, bemotrizinol is also known for its photostability. Many UV filters degrade when exposed to sunlight, reducing their protective effect over time. Bemotrizinol remains stable under prolonged UV exposure, which means it also acts as a stabilizer for other, less stable filters it’s blended with. Avobenzone, the most commonly used UVA filter in American sunscreens, is notoriously prone to this kind of breakdown. If your sunscreen contains avobenzone, it’s almost certainly combined with other ingredients whose only job is to stop the avobenzone from falling apart.
The molecular size of bemotrizinol is another reason dermatologists are enthusiastic about it. Chemically, bemotrizinol has larger light-absorbing molecules than other organic filters, making it less likely to cause adverse biological interactions. Researchers in pharmacology and dermatology use the “500 dalton rule,” in which molecules exceeding 500 daltons are generally too large to pass through the skin. Bemotrizinol exceeds that limit quite comfortably. It sits on top of the skin and does its job without significant absorption into the bloodstream, which has been a concern with some older chemical filters.
Why the U.S. Is Only Getting This Now
Bemotrizinol isn’t new. It was developed in the late 1990s by Swiss company Ciba Specialty Chemicals, and the European Union adopted it into sunscreens in 2000. Canada and several countries in Asia followed soon after. It has been used in Korean skincare brands and European pharmacy staples for roughly two decades. The reason Americans are only encountering it now comes down to a fundamental regulatory difference.
Many countries regulate sunscreens as cosmetics, but the U.S. treats them as over-the-counter drugs, requiring more extensive testing. This has led to Europe allowing some 30 ingredients in its sunscreens, while prior to Tuesday’s approval the U.S. had approved just over a dozen, the last in 1999.
As a drug, a sunscreen ingredient must clear a much higher evidentiary bar, including data on systemic absorption, long-term safety, and efficacy. DSM-Firmenich, the company behind bemotrizinol in the U.S. market, spent the past 20 years trying to gain approval for the ingredient, a process that has cost an estimated $18 million and advanced fitfully despite Congressional attempts in 2014 and 2020 to speed the process along.
The application was first filed with the FDA back in 2005. DSM began running a new round of FDA-requested studies in 2019. The proposed order finally came in December 2025, with a public comment period, and the final approval was issued on June 9, 2026, just seven months after the initial proposal, representing the first new sunscreen ingredient permitted in the United States since the late 1990s.
The approval was made possible through the streamlined administrative order process established by the 2020 CARES Act, which gave the FDA new tools to modify the OTC monograph more efficiently when supported by sound science.
The Gap It Closes
The regulatory delay has had real public health consequences, not just cosmetic ones. Most U.S. sunscreens prevent sunburn effectively when used correctly, but they generally are not as effective as European sunscreens at preventing the more subtle skin damage caused by UVA radiation. The Environmental Working Group estimates that most sunscreens sold in the U.S. would be too weak to qualify for the European Union market because they don’t filter UVA rays well enough.
That UVA gap has measurable consequences. Daily sunscreen use slashes cases of melanoma in half and reduces localized squamous cell carcinoma by 40 percent, according to a study that tested 1,600 people for four years and followed them for more than a decade afterward. But that protection depends on people actually using sunscreen, and that, in turn, depends on sunscreen that people want to put on their face. American sunscreens are often criticized for their unpleasant look or feel, which is part of why only 13 percent of American adults apply sunscreen every day.
Bemotrizinol may make its most practical difference right here. Because it covers both UV spectrums so effectively on its own, formulators can use fewer total filter ingredients to achieve the same protection, reducing the greasy, heavy texture that puts people off mineral and older chemical sunscreens. As the FDA’s proposed order noted, bemotrizinol had been marketed across Europe for years, and adding this filter lets U.S. manufacturers formulate products in a cosmetically elegant way.
What Comes Next for Consumers
Bemotrizinol will initially be sold in the U.S. by Dutch manufacturer DSM Nutritional Products under the brand name Parsol Shield, expected to launch later in 2026. After an 18-month exclusivity period, the ingredient will be available for use by other manufacturers. That means the first products on store shelves will carry the DSM name, but by late 2027 or 2028, you should expect to see bemotrizinol turning up across many mainstream sunscreen brands.
DSM Nutritional Products LLC submitted the OTC monograph order request to add bemotrizinol at concentrations up to 6%, and the FDA approved it at that level. For context, that’s the same concentration that European regulations permit. The agency classifies it as Generally Recognized As Safe and Effective (GRASE), the standard U.S. threshold for OTC drugs, for use in adults and children from six months of age.
There are still a few open questions. Researchers are investigating whether bemotrizinol degrades in pool water and whether any byproducts of that breakdown could cause skin irritation. Those aren’t settled concerns yet, and they’re worth watching as the ingredient enters broader use. But the FDA’s safety review, combined with over two decades of real-world use across Europe and Asia in enormous populations, has produced a safety profile that is, by most measures, among the most robust of any sunscreen filter available.
The approval also signals something bigger than one ingredient. FDA Commissioner Marty Makary said earlier this year that “the agency has historically moved too slowly in this area, leaving Americans with fewer options than consumers abroad,” and pledged to continue modernizing the regulation of sunscreen and other over-the-counter products. Whether that commitment translates into additional approvals of other European filters currently sitting in regulatory limbo remains to be seen.
Read More: Scientists Listened Inside the Sun and Discovered Something Unexpected
What This Actually Means
The sunscreen market in the U.S. has been functionally frozen since the late 1990s. The ingredients sitting in a typical American drugstore sunscreen today are largely the same ones that were sitting there when today’s 35-year-olds were in elementary school. Other countries moved on. The chemistry improved. The products got lighter, more wearable, more effective at blocking the UVA radiation that causes melanoma. Americans just didn’t have access to any of it.
The approval of bemotrizinol is expected to narrow the longstanding UVA protection gap between U.S. and European sunscreens, expand formulation options that are more photostable and cosmetically acceptable, and potentially support greater real-world sunscreen adherence. That last point is the one that should matter most to anyone thinking about their actual cancer risk. The best sunscreen is the one you use. Anything that makes sunscreen easier to wear every day without a second thought is, in the most literal sense, a public health improvement.
Skin cancer is the most common cancer in the United States, and dermatologists have spent years arguing that part of the problem is a sunscreen market that hasn’t kept up with the science. A product that offers genuine broad-spectrum protection, doesn’t sit heavy on the skin, and doesn’t leave a white cast is a product more people will actually reach for on an unremarkable Tuesday morning. That’s what this approval makes more possible. Getting the chemistry right took the better part of three decades. The products should start arriving before the end of summer.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.